<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00789555</url>
  </required_header>
  <id_info>
    <org_study_id>C-08-32</org_study_id>
    <nct_id>NCT00789555</nct_id>
  </id_info>
  <brief_title>Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis</brief_title>
  <official_title>Safety of PATANASE® Nasal Spray in Patients With Perennial Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess local nasal adverse effects, as well as systemic
      effects, of PATANASE nasal spray when compared with Patanase Vehicle, pH 3.7 and Patanase
      Vehicle, pH 7.0 in patients with perennial allergic rhinitis (PAR).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Clinically Relevant Change From Baseline (Day 0) in Nasal Examination Parameters to Exit (Month 12 or Sooner)</measure>
    <time_frame>Baseline (Day 0), Exit (Month 12 or sooner)</time_frame>
    <description>Percentage of subjects with clinically relevant change from baseline in protocol-specific safety parameters to time of exit, based on the assessment of the investigator, regardless of causality (related or not related) to test article.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-Rated Relief Assessment at Day 30</measure>
    <time_frame>Day 30</time_frame>
    <description>Relief assessment as rated by the subject on a 4-point scale, where 1=complete relief and 4=no relief. The subject answered the following question: &quot;I would rate the study medication's effectiveness for relieving my allergy symptoms since my last visit as: (1) Complete Relief; (2) Moderate Relief; (3) Mild Relief; (4) No Relief.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Change From Baseline (Day 0) in Pulse Rate Beats Per Minute (BPM) to Exit (Month 12 or Sooner)</measure>
    <time_frame>Baseline (Day 0), Exit (Month 12 or sooner)</time_frame>
    <description>Percentage of subjects with change from baseline in pulse measurement to time of exit, as recorded based on a full 60-second count after the patient rested for five minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Change From Baseline (Day 0) in Blood Pressure (Systolic) to Exit (Month 12 or Sooner)</measure>
    <time_frame>Baseline (Day 0), Exit (Month 12 or sooner)</time_frame>
    <description>Percentage of subjects with change from baseline in systolic blood pressure to time of exit, as obtained in a sitting position after the subject rested for five minutes. Two measurements, separated by two minutes, were obtained, from which the average systolic pressure was derived. If the first two readings differed by more than 5 millimeters of mercury (mmHg), a third reading was taken two minutes later and all three were used to determine the average. The first appearance of sound (phase 1) was used to define systolic blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Change From Baseline (Day 0) in Blood Pressure (Diastolic) to Exit (Month 12 or Sooner)</measure>
    <time_frame>Baseline (Day 0), Exit (Month 12 or sooner)</time_frame>
    <description>Percentage of subjects with change from baseline in diastolic blood pressure to time of exit, as obtained in a sitting position after the subject rested for five minutes. Two measurements, separated by two minutes, were obtained, from which the average systolic pressure was derived. If the first two readings differed by more than 5 millimeters of mercury (mmHg), a third reading was taken two minutes later and all three were used to determine the average. The disappearance of sound (phase 5) was used to define diastolic blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Clinically Relevant Change From Baseline (Day 0) in Physical Examination Parameters to Exit (Month 12 or Sooner)</measure>
    <time_frame>Baseline (Day 0), Exit (Month 12 or sooner)</time_frame>
    <description>Percentage of subjects with clinically relevant change from baseline in protocol-specific safety parameters to time of exit, based on the assessment of the investigator, regardless of causality (related or not related) to test article.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1260</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>PATANASE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olopatadine hydrochloride 0.6% nasal spray (PATANASE), two sprays in each nostril twice a day (morning and evening) for up to 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patanase Vehicle, pH 3.7</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Olopatadine nasal spray vehicle, pH 3.7, two sprays in each nostril twice a day (morning and evening) for up to 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patanase Vehicle, pH 7.0</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Olopatadine nasal spray vehicle, pH 7.0, two sprays in each nostril twice a day (morning and evening) for up to 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olopatadine hydrochloride 0.6% nasal spray (PATANASE)</intervention_name>
    <description>Two sprays in each nostril twice a day (morning and evening) for up to 12 months</description>
    <arm_group_label>PATANASE</arm_group_label>
    <other_name>PATANASE®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Olopatadine nasal spray vehicle, pH 3.7</intervention_name>
    <description>Two sprays in each nostril twice a day (morning and evening) for up to 12 months</description>
    <arm_group_label>Patanase Vehicle, pH 3.7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Olopatadine nasal spray vehicle, pH 7.0</intervention_name>
    <description>Two sprays in each nostril twice a day (morning and evening) for up to 12 months</description>
    <arm_group_label>Patanase Vehicle, pH 7.0</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Sign informed consent;

          2. Normal nasal exam;

          3. History of perennial allergic rhinitis;

          4. Allergy to perennial allergen documented by allergy testing;

          5. Age 12 years and older;

          6. Must follow instructions;

          7. Must make required study visits;

          8. Negative pregnancy test and adequate birth control methods for females of childbearing
             potential;

          9. Refrain from certain allergy medications during the study;

         10. Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          1. Nasal disorders;

          2. Use of substances that affect the nasal septum;

          3. Exposure to industrial metal plating solutions;

          4. Uncontrolled, severe, or unstable diseases;

          5. Hypersensitivity to the study drug or nasal spray components;

          6. Relative of site staff with access to the protocol;

          7. Participation in another investigational study within 30 days or at the same time as
             this study;

          8. Medical Monitor decision;

          9. Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Contact Alcon Call Center For Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2008</study_first_submitted>
  <study_first_submitted_qc>November 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <results_first_submitted>August 8, 2012</results_first_submitted>
  <results_first_submitted_qc>August 8, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 7, 2012</results_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nasal allergy</keyword>
  <keyword>nasal spray</keyword>
  <keyword>seasonal allergy</keyword>
  <keyword>perennial allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olopatadine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited and enrolled from 69 US study centers.</recruitment_details>
      <pre_assignment_details>234 subjects were enrolled under protocol Version 1.0, then exited due to a revision in the study plan. A new cohort of 1026 subjects was enrolled in protocol Version 2.0, for a total enrollment of 1260 subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PATANASE</title>
          <description>Two sprays in each nostril twice a day for up to 12 months</description>
        </group>
        <group group_id="P2">
          <title>Patanase Vehicle, pH 3.7</title>
          <description>Two sprays in each nostril twice a day for up to 12 months</description>
        </group>
        <group group_id="P3">
          <title>Patanase Vehicle, pH 7.0</title>
          <description>Two sprays in each nostril twice a day for up to 12 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="421"/>
                <participants group_id="P2" count="417"/>
                <participants group_id="P3" count="422"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="262"/>
                <participants group_id="P2" count="278"/>
                <participants group_id="P3" count="263"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
                <participants group_id="P2" count="139"/>
                <participants group_id="P3" count="159"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Amendment</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="80"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient decision unnrelated to adv event</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment failure</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PATANASE</title>
          <description>Two sprays in each nostril twice a day for up to 12 months</description>
        </group>
        <group group_id="B2">
          <title>Patanase Vehicle, pH 3.7</title>
          <description>Two sprays in each nostril twice a day for up to 12 months</description>
        </group>
        <group group_id="B3">
          <title>Patanase Vehicle, pH 7.0</title>
          <description>Two sprays in each nostril twice a day for up to 12 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="421"/>
            <count group_id="B2" value="417"/>
            <count group_id="B3" value="422"/>
            <count group_id="B4" value="1260"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.8" spread="14.5"/>
                    <measurement group_id="B2" value="36.2" spread="14.2"/>
                    <measurement group_id="B3" value="38.3" spread="14.6"/>
                    <measurement group_id="B4" value="37.1" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="251"/>
                    <measurement group_id="B2" value="260"/>
                    <measurement group_id="B3" value="278"/>
                    <measurement group_id="B4" value="789"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="144"/>
                    <measurement group_id="B4" value="471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="421"/>
                    <measurement group_id="B2" value="417"/>
                    <measurement group_id="B3" value="422"/>
                    <measurement group_id="B4" value="1260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Clinically Relevant Change From Baseline (Day 0) in Nasal Examination Parameters to Exit (Month 12 or Sooner)</title>
        <description>Percentage of subjects with clinically relevant change from baseline in protocol-specific safety parameters to time of exit, based on the assessment of the investigator, regardless of causality (related or not related) to test article.</description>
        <time_frame>Baseline (Day 0), Exit (Month 12 or sooner)</time_frame>
        <population>This analysis population includes all subjects who received study drug (Safety Analysis Set), minus any missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>PATANASE</title>
            <description>Two sprays in each nostril twice a day for up to 12 months</description>
          </group>
          <group group_id="O2">
            <title>Patanase Vehicle, pH 3.7</title>
            <description>Two sprays in each nostril twice a day for up to 12 months</description>
          </group>
          <group group_id="O3">
            <title>Patanase Vehicle, pH 7.0</title>
            <description>Two sprays in each nostril twice a day for up to 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Clinically Relevant Change From Baseline (Day 0) in Nasal Examination Parameters to Exit (Month 12 or Sooner)</title>
          <description>Percentage of subjects with clinically relevant change from baseline in protocol-specific safety parameters to time of exit, based on the assessment of the investigator, regardless of causality (related or not related) to test article.</description>
          <population>This analysis population includes all subjects who received study drug (Safety Analysis Set), minus any missing data.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="386"/>
                <count group_id="O2" value="386"/>
                <count group_id="O3" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anatomic Abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possible Ulcerations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Change From Baseline (Day 0) in Pulse Rate Beats Per Minute (BPM) to Exit (Month 12 or Sooner)</title>
        <description>Percentage of subjects with change from baseline in pulse measurement to time of exit, as recorded based on a full 60-second count after the patient rested for five minutes.</description>
        <time_frame>Baseline (Day 0), Exit (Month 12 or sooner)</time_frame>
        <population>Safety Analysis Set, minus any missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>PATANASE</title>
            <description>Two sprays in each nostril twice a day for up to 12 months</description>
          </group>
          <group group_id="O2">
            <title>Patanase Vehicle, pH 3.7</title>
            <description>Two sprays in each nostril twice a day for up to 12 months</description>
          </group>
          <group group_id="O3">
            <title>Patanase Vehicle, pH 7.0</title>
            <description>Two sprays in each nostril twice a day for up to 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Change From Baseline (Day 0) in Pulse Rate Beats Per Minute (BPM) to Exit (Month 12 or Sooner)</title>
          <description>Percentage of subjects with change from baseline in pulse measurement to time of exit, as recorded based on a full 60-second count after the patient rested for five minutes.</description>
          <population>Safety Analysis Set, minus any missing data.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="416"/>
                <count group_id="O2" value="414"/>
                <count group_id="O3" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease greater than 30 BPM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease 21-30 BPM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease 11-20 BPM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                    <measurement group_id="O2" value="9.2"/>
                    <measurement group_id="O3" value="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease 1-10 BPM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2"/>
                    <measurement group_id="O2" value="30.4"/>
                    <measurement group_id="O3" value="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                    <measurement group_id="O2" value="6.5"/>
                    <measurement group_id="O3" value="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase 1-10 BPM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7"/>
                    <measurement group_id="O2" value="38.9"/>
                    <measurement group_id="O3" value="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase 11-20 BPM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8"/>
                    <measurement group_id="O2" value="9.9"/>
                    <measurement group_id="O3" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase 21-30 BPM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="3.6"/>
                    <measurement group_id="O3" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase greater than 30 BPM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.2"/>
                    <measurement group_id="O3" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Change From Baseline (Day 0) in Blood Pressure (Systolic) to Exit (Month 12 or Sooner)</title>
        <description>Percentage of subjects with change from baseline in systolic blood pressure to time of exit, as obtained in a sitting position after the subject rested for five minutes. Two measurements, separated by two minutes, were obtained, from which the average systolic pressure was derived. If the first two readings differed by more than 5 millimeters of mercury (mmHg), a third reading was taken two minutes later and all three were used to determine the average. The first appearance of sound (phase 1) was used to define systolic blood pressure.</description>
        <time_frame>Baseline (Day 0), Exit (Month 12 or sooner)</time_frame>
        <population>Safety Analysis Set, minus any missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>PATANASE</title>
            <description>Two sprays in each nostril twice a day for up to 12 months</description>
          </group>
          <group group_id="O2">
            <title>Patanase Vehicle, pH 3.7</title>
            <description>Two sprays in each nostril twice a day for up to 12 months</description>
          </group>
          <group group_id="O3">
            <title>Patanase Vehicle, pH 7.0</title>
            <description>Two sprays in each nostril twice a day for up to 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Change From Baseline (Day 0) in Blood Pressure (Systolic) to Exit (Month 12 or Sooner)</title>
          <description>Percentage of subjects with change from baseline in systolic blood pressure to time of exit, as obtained in a sitting position after the subject rested for five minutes. Two measurements, separated by two minutes, were obtained, from which the average systolic pressure was derived. If the first two readings differed by more than 5 millimeters of mercury (mmHg), a third reading was taken two minutes later and all three were used to determine the average. The first appearance of sound (phase 1) was used to define systolic blood pressure.</description>
          <population>Safety Analysis Set, minus any missing data.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="416"/>
                <count group_id="O2" value="413"/>
                <count group_id="O3" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease greater than 30 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease 21-30 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="2.4"/>
                    <measurement group_id="O3" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease 11-20 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8"/>
                    <measurement group_id="O2" value="9.2"/>
                    <measurement group_id="O3" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease 1-10 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3"/>
                    <measurement group_id="O2" value="36.3"/>
                    <measurement group_id="O3" value="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase 1-10 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1"/>
                    <measurement group_id="O2" value="33.4"/>
                    <measurement group_id="O3" value="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase 11-20 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6"/>
                    <measurement group_id="O2" value="10.2"/>
                    <measurement group_id="O3" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase 21-30 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.9"/>
                    <measurement group_id="O3" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase greater than 30 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Change From Baseline (Day 0) in Blood Pressure (Diastolic) to Exit (Month 12 or Sooner)</title>
        <description>Percentage of subjects with change from baseline in diastolic blood pressure to time of exit, as obtained in a sitting position after the subject rested for five minutes. Two measurements, separated by two minutes, were obtained, from which the average systolic pressure was derived. If the first two readings differed by more than 5 millimeters of mercury (mmHg), a third reading was taken two minutes later and all three were used to determine the average. The disappearance of sound (phase 5) was used to define diastolic blood pressure.</description>
        <time_frame>Baseline (Day 0), Exit (Month 12 or sooner)</time_frame>
        <population>Safety Analysis Set, minus any missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>PATANASE</title>
            <description>Two sprays in each nostril twice a day for up to 12 months</description>
          </group>
          <group group_id="O2">
            <title>Patanase Vehicle, pH 3.7</title>
            <description>Two sprays in each nostril twice a day for up to 12 months</description>
          </group>
          <group group_id="O3">
            <title>Patanase Vehicle, pH 7.0</title>
            <description>Two sprays in each nostril twice a day for up to 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Change From Baseline (Day 0) in Blood Pressure (Diastolic) to Exit (Month 12 or Sooner)</title>
          <description>Percentage of subjects with change from baseline in diastolic blood pressure to time of exit, as obtained in a sitting position after the subject rested for five minutes. Two measurements, separated by two minutes, were obtained, from which the average systolic pressure was derived. If the first two readings differed by more than 5 millimeters of mercury (mmHg), a third reading was taken two minutes later and all three were used to determine the average. The disappearance of sound (phase 5) was used to define diastolic blood pressure.</description>
          <population>Safety Analysis Set, minus any missing data.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="416"/>
                <count group_id="O2" value="413"/>
                <count group_id="O3" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease greater than 30 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.2"/>
                    <measurement group_id="O3" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease 21-30 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="1.0"/>
                    <measurement group_id="O3" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease 11-20 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                    <measurement group_id="O2" value="13.6"/>
                    <measurement group_id="O3" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease 1-10 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5"/>
                    <measurement group_id="O2" value="38.7"/>
                    <measurement group_id="O3" value="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                    <measurement group_id="O2" value="6.1"/>
                    <measurement group_id="O3" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase 1-10 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2"/>
                    <measurement group_id="O2" value="33.4"/>
                    <measurement group_id="O3" value="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase 11-20 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="6.5"/>
                    <measurement group_id="O3" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase 21-30 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase greater than 30 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Clinically Relevant Change From Baseline (Day 0) in Physical Examination Parameters to Exit (Month 12 or Sooner)</title>
        <description>Percentage of subjects with clinically relevant change from baseline in protocol-specific safety parameters to time of exit, based on the assessment of the investigator, regardless of causality (related or not related) to test article.</description>
        <time_frame>Baseline (Day 0), Exit (Month 12 or sooner)</time_frame>
        <population>Safety Analysis Set, minus any missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>PATANASE</title>
            <description>Two sprays in each nostril twice a day for up to 12 months</description>
          </group>
          <group group_id="O2">
            <title>Patanase Vehicle, pH 3.7</title>
            <description>Two sprays in each nostril twice a day for up to 12 months</description>
          </group>
          <group group_id="O3">
            <title>Patanase Vehicle, pH 7.0</title>
            <description>Two sprays in each nostril twice a day for up to 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Clinically Relevant Change From Baseline (Day 0) in Physical Examination Parameters to Exit (Month 12 or Sooner)</title>
          <description>Percentage of subjects with clinically relevant change from baseline in protocol-specific safety parameters to time of exit, based on the assessment of the investigator, regardless of causality (related or not related) to test article.</description>
          <population>Safety Analysis Set, minus any missing data.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="403"/>
                <count group_id="O3" value="392"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Head/EENT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2"/>
                    <measurement group_id="O2" value="4.2"/>
                    <measurement group_id="O3" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neck</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.2"/>
                    <measurement group_id="O3" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdomen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and Extremities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurological</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph Nodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.2"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Self-Rated Relief Assessment at Day 30</title>
        <description>Relief assessment as rated by the subject on a 4-point scale, where 1=complete relief and 4=no relief. The subject answered the following question: &quot;I would rate the study medication's effectiveness for relieving my allergy symptoms since my last visit as: (1) Complete Relief; (2) Moderate Relief; (3) Mild Relief; (4) No Relief.&quot;</description>
        <time_frame>Day 30</time_frame>
        <population>Analysis population included all subjects enrolled under protocol Version 2.0 who received study drug and attended at least one on-therapy study visit (ITT). The LOCF (last observation carried forward method) was used to impute missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>PATANASE</title>
            <description>Two sprays in each nostril twice a day for up to 12 months</description>
          </group>
          <group group_id="O2">
            <title>Patanase Vehicle, pH 3.7</title>
            <description>Two sprays in each nostril twice a day for up to 12 months</description>
          </group>
          <group group_id="O3">
            <title>Patanase Vehicle, pH 7.0</title>
            <description>Two sprays in each nostril twice a day for up to 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Self-Rated Relief Assessment at Day 30</title>
          <description>Relief assessment as rated by the subject on a 4-point scale, where 1=complete relief and 4=no relief. The subject answered the following question: &quot;I would rate the study medication's effectiveness for relieving my allergy symptoms since my last visit as: (1) Complete Relief; (2) Moderate Relief; (3) Mild Relief; (4) No Relief.&quot;</description>
          <population>Analysis population included all subjects enrolled under protocol Version 2.0 who received study drug and attended at least one on-therapy study visit (ITT). The LOCF (last observation carried forward method) was used to impute missing data.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="328"/>
                <count group_id="O2" value="331"/>
                <count group_id="O3" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.9"/>
                    <measurement group_id="O2" value="2.7" spread="1.0"/>
                    <measurement group_id="O3" value="2.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for the duration of the study: 2 years, 1 month, 16 days. Adverse events were defined as any untoward (unfavorable and unintended) medical occurrence in a subject administered a test article.</time_frame>
      <desc>Adverse events were collected after the first dose of study medication at Visit 1 and during each monthly on-therapy study visit through Visit 13 (or Early Exit). Safety Analysis Set was used for analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>PATANASE</title>
          <description>Two sprays in each nostril twice a day for up to 12 months</description>
        </group>
        <group group_id="E2">
          <title>Patanase Vehicle, pH 3.7</title>
          <description>Two sprays in each nostril twice a day for up to 12 months</description>
        </group>
        <group group_id="E3">
          <title>Patanase Vehicle, pH 7.0</title>
          <description>Two sprays in each nostril twice a day for up to 12 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Herpes zoster oticus</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <description>Related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intravertebral disc protrusion</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Jaw disorder</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of the cervix</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cystostomy closure</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Internal fixation of fracture</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Spinal fusion surgery</sub_title>
                <description>Not related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="220" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="213" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="214" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="422"/>
              </event>
              <event>
                <sub_title>Nasal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="421"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="417"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="422"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Alcon reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Terri Pasquine, Sr. Clinical Lead</name_or_title>
      <organization>Alcon Research</organization>
      <phone>817-551-4760</phone>
      <email>terri.pasquine@alconlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

